Date: 2015-01-29
Type of information: Opening of new premises
Compound: clinical development unit in New Jersey
Company: Symphogen (Denmark)
Therapeutic area: Cancer - Oncology
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On January 29, 2015, Symphogen announced several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. Symphogen announced that Symphogen Inc. is opening a Clinical Development Unit in New Jersey, US, under the leadership of Head of Corporate R&D, Chief Medical & Scientific Officer Dr. Ivan Horak. Additionally, Dr. Esper Boel has joined the company as Chief Technology Officer to lead Symphogen's antibody discovery activities in Denmark, including Immuno-Oncology projects. Prior to joining Symphogen, Dr. Boel served as Corporate Vice President for the Biotechnology unit in Novo Nordisk's international R&D organization. Dr. Boel has extensive experience in biopharmaceutical R&D management, and has served as Board member/consultant for high-profile antibody based companies including Xencor Inc. and Innate Pharma SA, and he has (co)authored more than 70 original research articles and reviews.
- Symphogen also expects to bring its Pan-HER multi-targeting antibody mixture into clinical development in 2015. Pan-HER is a mixture of six humanized full-length monoclonal antibodies targeting EGFR, HER2 and HER3, all validated targets for cancer treatment that effectively induces simultaneous down-modulation of all three targets and prevents compensatory receptor up-regulation. Symphogen also has, in late preclinical development, a mAb mixture program against the receptor tyrosine kinase c-MET, which is expected to enter the clinic in 2016. Symphogen\'s early discovery activities will now be focused on the development of multi-targeting programs in the immuno-oncology area. The company has just regained the rights to Sym004 and looks forward to rapidly moving forward its clinical development in areas of high unmet medical needs.
Financial terms:
Latest news:
Is general: Yes
